Literature DB >> 25233404

Astrocytosis in infantile neuronal ceroid lipofuscinosis: friend or foe?

Charles Shyng1, Mark S Sands.   

Abstract

Infantile neuronal ceroid lipofuscinosis (INCL; infantile Batten disease) is an inherited paediatric neurodegenerative disease. INCL is caused by a deficiency in the lysosomal enzyme palmitoyl-protein thioesterase-1 (PPT1) and is thus classified as a lysosomal storage disease. Pathological examination of both human and murine INCL brains reveals progressive, widespread neuroinflammation. In fact, astrocyte activation appears to be the first histological sign of disease. However, the role of astrocytosis in INCL was poorly understood. The hallmark of astrocyte activation is the up-regulation of intermediate filaments, such as glial fibrillary acidic protein (GFAP) and vimentin. The role of astrocytosis in INCL was studied in a murine model lacking PPT1 and the intermediate filaments GFAP and vimentin (triple-knockout). This murine model of INCL with attenuated astrocytosis had an exacerbated pathological and clinical phenotype. The triple-knockout mouse had a significantly shortened lifespan, and accelerated cellular and humoural neuroinflammatory response compared with the parental PPT1(-/-) mouse. The data obtained from the triple-knockout mouse strongly suggest that astrocyte activation plays a beneficial role in early INCL disease progression. A more thorough understanding of the glial responses to lysosomal enzyme deficiencies and the accumulation of undergraded substrates will be crucial to developing effective therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25233404     DOI: 10.1042/BST20140188

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  7 in total

1.  Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis.

Authors:  Arunava Ghosh; Suresh Babu Rangasamy; Khushbu K Modi; Kalipada Pahan
Journal:  J Neurochem       Date:  2017-04-03       Impact factor: 5.372

Review 2.  Astrocytes and lysosomal storage diseases.

Authors:  K V Rama Rao; T Kielian
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

3.  Characterization of neurological disease progression in a canine model of CLN5 neuronal ceroid lipofuscinosis.

Authors:  Elizabeth J Meiman; Grace Robinson Kick; Cheryl A Jensen; Joan R Coates; Martin L Katz
Journal:  Dev Neurobiol       Date:  2022-04-28       Impact factor: 3.102

Review 4.  Endosomal-Lysosomal Processing of Neurodegeneration-Associated Proteins in Astrocytes.

Authors:  Ching-On Wong
Journal:  Int J Mol Sci       Date:  2020-07-21       Impact factor: 5.923

5.  Clinically early-stage CSPα mutation carrier exhibits remarkable terminal stage neuronal pathology with minimal evidence of synaptic loss.

Authors:  Bruno A Benitez; Nigel J Cairns; Robert E Schmidt; John C Morris; Joanne B Norton; Carlos Cruchaga; Mark S Sands
Journal:  Acta Neuropathol Commun       Date:  2015-11-26       Impact factor: 7.801

6.  Neuronal Ceroid Lipofuscinosis in a Domestic Cat Associated with a DNA Sequence Variant That Creates a Premature Stop Codon in CLN6.

Authors:  Martin L Katz; Reuben M Buckley; Vanessa Biegen; Dennis P O'Brien; Gayle C Johnson; Wesley C Warren; Leslie A Lyons
Journal:  G3 (Bethesda)       Date:  2020-08-05       Impact factor: 3.154

7.  Comparative proteomic profiling reveals mechanisms for early spinal cord vulnerability in CLN1 disease.

Authors:  Hemanth R Nelvagal; Maica Llavero Hurtado; Samantha L Eaton; Rachel A Kline; Douglas J Lamont; Mark S Sands; Thomas M Wishart; Jonathan D Cooper
Journal:  Sci Rep       Date:  2020-09-16       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.